Results 61 to 70 of about 170,256 (261)

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

Advanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu, Jun Yang, Yuhang Zhang, Xiaoli Xue   +3 more
wiley   +1 more source

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

PLoS ONE, 2021
BackgroundThe phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its
Qiao Liu, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, Xiaohui Zeng   +7 more
doaj   +1 more source

AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial‐Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C‐Dependent Stabilization of Snail mRNA

Advanced Science, EarlyView.
Proposed molecular mechanism: NSUN6 catalyzes m5C methylation on Snail mRNA to enhance its stability, leading to Snail upregulation and EMT promotion. The first‐in‐class inhibitor AL398 suppresses endometrial cancer metastasis by targeting the NSUN6‐m5C‐Snail. axis. ABSTRACT Endometrial cancer (EC) constitutes a leading gynecologic malignancy for which
Xiangzhuan Zhao, Linlin Yang, Huanxiang Chen, Chenfeng Guo, Hongshen Lu, Ying Zhu, Xuanzhi Wang, Yang Li, Ruike Zhang, Zichong Huang, Yifang Chen, Keyu Jin, Zeduo Xu, Lingxiu Meng, Longfeng Zhang, Yuanyuan Han, Yicong Yan, Qiaozhen Kang, Junhu Wan, Hongyang Liu   +19 more
wiley   +1 more source

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

BMC Cancer
Background Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC).
Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit   +15 more
doaj   +1 more source

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

Journal for ImmunoTherapy of Cancer, 2020
Background To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential.
Annelies Jorritsma-Smit, Elisabeth G E de Vries, Danique Giesen, Marjolijn N Lub-de Hooge, Elly L van der Veen, Linda Pot-de Jong   +5 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

Advanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai, Xin Mei Zhang, Jing Cheng Zhang, Xu Ting Deng, Qiao Liu, Mustafa Hussein Ali, Fang Zhou Yin, Wu Yin   +7 more
wiley   +1 more source

Pembrolizumab for early triple-negative breast cancer

, 2020
Background: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer.
McArthur, H., Dent, R., Schmid, P., Harbeck, N., Cardoso, F., Foukakis, T., Aktan, G., Pusztai, L., Kümmel, S., Hui, R., O'Shaughnessy, J., Cortes, J., Takahashi, M., Park, Y. H., Bergh, J., Karantza, V., Denkert, C., Fasching, P. A., Zhao, J., Jia, L., Untch, M.   +20 more
core   +1 more source

Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma

Animal Models and Experimental Medicine, EarlyView.
A zebrafish xenograft model accurately distinguishes metastatic from non‐metastatic HNSCC and recapitulates cisplatin sensitivity/resistance patterns. Using patient‐derived tumors, it predicts individual therapeutic responses, offering a rapid, clinically applicable platform for guiding personalized treatment. Abstract Background Head and neck squamous
Lu Chen, Shu Sun, Yujia Liu, Liehao Jiang, Cuiyun Wu, Ting Liu, Yujiao Zhao, Yuwei Liu, Lu Liu, Qi Wang, Xiaowei Zheng, Ping Huang   +11 more
wiley   +1 more source